RRX-001
RRX-001 (RRX001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity; targets CD133 + /CD44 + cancer stem cells from colon cancer cell-lines, HT-29, Caco-2, and HCT116, and inhibits Wnt pathway signalling with downregulation of c-Myc; inhibits HCT 116 and decreases levels of the DNA methyltransferases DNMT1 and DNMT3a in a time and dose-dependent manner; RRX-001 (RRX001) is a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia.Lung Cancer Phase 2 Clinical.
Product Specifications
CAS Number
925206-65-1
Product Name Alternative
RRX001 | RRX 001
Purity
>98% (HPLC)
Solubility
DMSO : ≥ 100 mg/mL 373.11 mM
Smiles
O=[N+] (C1 ([N+] ([O-]) =O) CN (C (CBr) =O) C1) [O-]
Molecular Formula
C5H6BrN3O5
Molecular Weight
268.023
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2-bromo-1- (3,3-dinitroazetidin-1-yl) ethan-1-one
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ZNF358, NT (ZNF358, Zinc finger protein 358) (MaxLight 650) discontinued
GINS2 (PSF2, DNA Replication Complex GINS Protein PSF2, GINS Complex Subunit 2, CGI-122, DC5, HSPC037)
